Heart disease and depression: Don't ignore the relationship

Cleveland Clinic Journal of Medicine

Volumn 70, Issue 9, 2003, Pages 745-761

  Kemp, David Eric ^a   Malhotra, Shishuka ^c   Franco, Kathleen N ^b   Tesar, George ^b   Bronson, David L ^b  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; CITALOPRAM; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PAROXETINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL; WARFARIN;

APPETITE DISORDER; AUTONOMIC NERVOUS SYSTEM FUNCTION; BODY WEIGHT DISORDER; BRADYCARDIA; CORONARY ARTERY BYPASS GRAFT; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HOSPITALIZATION; HUMAN; INSOMNIA; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; MORTALITY; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; PATIENT MONITORING; PATIENT REFERRAL; PHOTOTHERAPY; PREDICTION; PROGNOSIS; PSYCHIATRIC TREATMENT; PSYCHOTHERAPY; RATING SCALE; RESTLESSNESS; REVIEW; RISK FACTOR; SAFETY; SELF CONCEPT; SEXUAL DYSFUNCTION; SOCIAL SUPPORT; SUICIDAL BEHAVIOR; SYMPTOM; SYNCOPE; TACHYCARDIA; THROMBOCYTE ACTIVATION; UNSTABLE ANGINA PECTORIS;

EID: 0141563687     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.9.745     Document Type: Review

References (104)

1. Blazer DG. Mood disorders: epidemiology. In: Sadock BJ, Sadock VA, editors. Comprehensive Textbook of Psychiatry, Seventh Edition. Philadelphia: Lippincott, Williams and Wilkins, 2000:1298-1308.
2. Kay J. Psychiatry: Behavioral Science and Clinical Essentials. Philadelphia: W.B. Saunders, 2000.
3. Crum RM, Cooper-Patrick L, Ford DE. Depressive symptoms among general medical patients: prevalence and one-year outcome. Psychosom Med 1994; 56:109-117.
4. Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349:1436-1442.
5. American Heart Association. Heart Attack and Stroke Facts. Dallas: American Heart Association, 1998.
6. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999; 99:2192-2217.
7. Jiang W, Krishnan RR, O'Connor CM. Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs 2002; 16:111-127.
8. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. Circulation 1996; 94:3123-3129.
9. Anda R, Williamson D, Jones D, et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology 1993; 4:285-294.
10. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149:1785-1789.
11. Carney RM, Rich MW, Freedland KE, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988; 50:627-633.
12. Gold PW, Chrousos GP. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc Assoc Am Physicians 1999; 111:22-34.
13. Murphy JM, Monson RR, Olivier DC, Sobol AM, Leighton AH. Affective disorders and mortality: a general population study. Arch Gen Psychiatry 1987; 44:473-480.
14. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993; 15:1819-1825.
15. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91:999-1005.
16. Barefoot JC, Helms MJ, Mark DB, et al. Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol 1996; 78:613-617.
17. Lesperance F, Frasure-Smith N, Juneau M, Theroux P. Depression and 1-year prognosis in unstable angina. Arch Intern Med 2000; 160:1354-1360.
18. Penninx BW, Beekman AT, Honig A, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001; 58:221-227.
19. Horwath E, Johnson J, Klerman GL, Weissman MM. Depressive symptoms as relative and attributable risk factors for first-onset major depression. Arch Gen Psychiatry 1992; 49:817-823.
20. Burker EJ, Blumenthal JA, Feldman M, et al. Depression in male and female patients undergoing cardiac surgery. Br J Clin Psychol 1995; 34:119-128.
21. Scheier MF, Matthews KA, Owens JF, et al. Optimism and rehospitalization after coronary artery bypass graft surgery. Arch Intern Med 1999; 159:829-835.
22. Connerney I, Shapiro PA, McLaughlin JS, Bagiella E, Sloan RP. Relation between depression after coronary artery bypass surgery and 12-month outcome: a prospective study. Lancet 2001; 358:1766-1771.
23. Nemeroff CB. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry 1996; 1:336-342.
24. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology and treatment. Arch Gen Psychiatry 1998; 55:580-592.
25. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49:391-404.
26. World Health Organization Collaborative Study. The dexamethasone suppression test in depression. Br J Psychiatry 1987; 150:459-462.
27. Malhotra S, Tesar GE, Franco K. The relationship between depression and cardiovascular disorders. Curr Psychiatry Rep 2000; 2:241-246.
28. Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest 1996; 26:353-370.
29. Wilson JD, Foster DW, Kronenberg HM, Larsen PR. Williams Textbook of Endocrinology, Ninth Edition. Philadelphia: W.B. Saunders; 1998.
30. Roy A, Pickar D, De Jong J, Karoum F, Linnoila M. Norepinephrine and its metabolites in cerebrospinal fluid, plasma and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch Gen Psychiatry 1988; 45:849-857.
31. Roy A, Linnoila M, Karoum F, Pickar D. Urinary-free cortisol in depressed patients and controls: relationship to urinary indices of noradrenergic function. Psychol Med 1988; 18:93-98.
32. Roy A, Guthrie S, Pickar D, Linnoila M. Plasma norepinephrine responses to cold challenge in depressed patients and normal controls. Psychiatry Res 1987; 21:161-168.
33. Roy A, Pickar D, Linnoila M, Potter WZ. Plasma norepinephrine level in affective disorders: relationship to melancholia. Arch Gen Psychiatry 1985; 42:1181-1185.
34. Shimbo D, Child J, Davidson K, et al. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol 2002; 89:331-333.
35. Nemeroff CB, Knight DL, Franks J, Craighead WE, Krishman KRR. Further studies on platelet serotonin transporter binding in depression. Am J Psychiatry 1994; 151:1623-1625.
36. Cerrito F, Lazzaro MP, Gaudio E, Arminio P, Aloisi G. 5HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci 1993; 53:209-215.
37. Gorman JM, Sloan RP. Heart rate variability in depressive and anxiety disorders. Am Heart J 2000; 140(suppl 4):77-83.
38. Malaspina D, Dalack G, Leitman D. Low heart rate variability is not caused by typical neuroleptics in schizophrenia patients. CNS Spectrums 2002; 7:53-57.
39. Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate variability and acute myocardial infarction. Circulation 2001; 104:2024-2028.
40. Braunwald E, Zipes DP, Libby P. Heart Disease: A Textbook of Cardiovascular Medicine, Sixth Edition. Philadelphia: W.B. Saunders; 2001:89-90,1099-1100,1200.
41. Klein E, Cnaani E, Harel T, Braun S, Ben-Haim SA. Altered heart rate variability in panic disorder patients. Biol Psychiatry 1995; 37:18-24.
42. American College of Cardiology Cardiovascular Technology Assessment Committee. Heart rate variability for risk stratification of life-threatening arrhythmias. J Am Coll Cardiol 1993; 22:948-950.
43. Cripps TR, Malik M, Farrell TG, Camm AJ. Prognostic value of reduced heart rate variability after myocardial infarction: clinical evaluation of a new analysis method. Br Heart J 1991; 65:14-19.
44. Van Ravenswaaij-Arts CM, Kollee LA, Hopman JC, Stoelinga GB, van Geijn HP. Heart rate variability. Ann Intern Med 1993; 118:436-447.
45. Dalack GW, Roose SP. Perspectives on the relationship between cardiovascular disease and affective disorder. J Clin Psychiatry 1990; 51(suppl):4-9.
46. Viskin S, Belhassen B. Noninvasive and invasive strategies for the prevention of sudden death after myocardial infarction: value, limitations and implications for therapy. Drugs 1992; 44:336-355.
47. Sloan RP, Shapiro PA, Bagiella E, Myers MM, Gorman JM. Cardiac autonomic control buffers blood pressure variability responses to challenge: a psychophysiologic model of coronary artery disease. Psychosom Med 1999:61:58-68.
48. Ahern DK, Gorkin L, Anderson JL, et al. Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol 1990; 66:59-62.
49. Perez-Stable EJ, Miranda J, Munoz RF, Ying YW. Depression in medical outpatients. Underrecognition and misdiagnosis. Arch Intern Med 1990; 150:1083-1088.
50. Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997; 277:333-340.
51. Freedland KE, Lustman PJ, Carney RM, Hong BA. Underdiagnosis of depression in patients with coronary artery disease: the role of nonspecific symptoms. Int J Psychiatry Med 1992; 3:221-229.
52. Endicott J. Measurement of depression in patients with cancer. Cancer 1984; 53(suppl 10):2243-2249.
53. Freedland KE, Carney RM, Lustman PJ, Rich MW, Jaffe AS. Major depression in coronary artery disease patients with versus without a prior history of depression. Psychosom Med 1992; 54:416-421.
54. Cavanaugh S. Depression in the medically ill: critical issues in diagnostic assessment. Psychosomatics 1995; 36:48-59.
55. Beck AT, Ward CH, Mendelson M, et al. An inventory of measuring depression. Arch Gen Psychiatry 1961; 4:53-63.
56. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965; 12:63-70.
57. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med 2000; 343:1942-1948.
58. Swartz HA, Markowitz JC. Time-limited psychotherapy. In: Tasman A, Kay J, Lieberman J, editors. Psychiatry. Philadelphia: W.B. Saunders; 1997:1405-1417.
59. Thase ME, Wright JH. Cognitive and behavioral therapies. In: Tasman A, Kay J, Lieberman J, editors. Psychiatry. Philadelphia: W.B. Saunders; 1997,1418-1438.
60. CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-412.
61. CAST II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227-233.
62. Bigger JT, Giardina EG, Perel JM, Kantor SJ, Glassman AH. Cardiac antiarrhythmic effect of imipramine hydrochloride. N Engl J Med 1977; 296:206-208.
63. Roose SP, Glassman AH, Dalack GW. Depression, heart disease and tricyclic antidepressants. J Clin Psychiatry 1989; 50(suppl 7):12-18.
64. Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB. Comparison of imipramine and nortriptyline-induced orthostatic hypotension: a meaningful difference. J Clin Psychopharmacol 1981; 1:316-319.
65. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine and sertraline in primary care: a randomized trial. JAMA 2001; 286:2947-2955.
66. Ellison JM, Milofsky JE, Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1990; 51:385-386.
67. Feder R. Bradycardia and syncope induced by fluoxetine. J Clin Psychiatry 1991; 52:139.
68. Rodriguez de la Torre B, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001; 23:435-440.
69. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EG, Bigger JT Jr. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998; 155:660-665.
70. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279:287-291.
71. Shapiro PA, Lesperance F, Frasure-Smith N. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHART Trial). Sertraline Anti-Depressant Heart Attack Trial. Am Heart J 1999; 137:1100-1106
72. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288:701-709.
73. Balogh S, Fitzpatrick DF, Hendricks SE, Paige SR. Increases in heart rate variability with successful treatment in patients with major depressive disorder. Psychopharmacol Bull 1993; 29:201-206.
74. Khaykin Y, Dorian P, Baker B, et al. Autonomic correlates of antidepressant treatment using heart-rate variability analysis. Can J Psychiatry 1998; 43:183-186.
75. Pollock BG, Laghrissi-Thode F, Wagner WR, et al. Increased platelet factor 4 and beta thromboglobulin in depressed patients with ischemic heart disease. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; Dec 11-14, 1995; San Juan, Puerto Rico.
76. DasGupta K. Treatment of depression in elderly patients: recent advances. Arch Fam Med 1998; 7:274-280.
77. Masand PS, Tesar GE. Use of stimulants in the medically ill. Psychiatr Clin North Am 1996; 19:515-547.
78. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991; 148:512-516.
79. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995; 56:574-579.
80. Zielinski RJ, Roose SP, Devanand DP. Cardiovascular complications of ECT in depressed patients with cardiac disease. Am J Psychiatry 1993; 150:904-909.
81. Mayou RA, Gill D, Thompson DR, et al. Depression and anxiety as predictors of outcome after myocardial infarction. Psychosom Med 2000; 62:212-219.
82. Lloyd GG, Cawley RH. Distress or illness? A study of psychological symptoms after myocardial infarction. Br J Psychiatry 1983; 142:120-125.
83. Hlatky MA, Haney T, Barefoot JC, et al. Medical, psychological and social correlates of work disability among men with coronary artery disease. Am J Cardiol 1986; 58:911-915.
84. Frasure-Smith N, Lesperance F, Gravel G, et al. Depression and healthcare costs during the first year following myocardial infarction. J Psychosom Res 2000; 48:471-478.
85. Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 2000; 160:1818-1823.
86. Everson SA, Goldberg DE, Kaplan GA, et al. Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom Med 1996; 58:113-121.
87. Krishnan KR, George LK, Pieper CF, et al. Depression and social support in elderly patients with cardiac disease. Am Heart J 1998; 136:491-495.
88. Ruberman W, Weinblatt E, Goldberg JD, Chaudhary BS. Psychosocial influences on mortality after myocardial infarction. N Engl J Med 1984; 311:552-559.
89. Orth-Gomer K, Unden AL, Edwards ME. Social isolation and mortality in ischemic heart disease: a 10-year follow-up study of 150 middle aged men. Acta Med Scand 1988; 224:205-215.
90. Barefoot JC, Brummett BH, Clapp-Channing NE, et al. Moderators of the effect of social support on depressive symptoms in cardiac patients. Am J Cardiol 2000; 86:438-442.
91. The ENRICHD Investigators. Enhancing Recovery in Coronary Heart Disease (ENRICHD) study intervention: rationale and design. Psychosom Med 2001; 63:747-755.
92. Ladwig KH, Roll G, Breithardt G, Budde T, Borggrefe M. Post-infarction depression and incomplete recovery 6 months after acute myocardial infarction. Lancet 1994; 343:20-23.
93. Aromaa A, Raitasalo R, Reunanen A, et al. Depression and cardiovascular disease. Acta Psychiatr Scand Suppl 1994; 377:77-82.
94. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996; 93:1976-1980.
95. Ford DE, Mead LA, Chang PP, Cooper-Patrick L, Wang NY, Klag MJ. Depression is a risk factor for coronary artery disease in men: the precursors study. Arch Intern Med 1998; 158:1422-1426.
96. Ferketich AK, Schwartzbaum JA, Frid DJ, Moeschberger ML. Depression as an antecedent to heart disease among women and men in the NHANES I study. National Health and Nutrition Examination Survey. Arch Intern Med 2000; 160:1261-1268.
97. Ariyo AA, Haan M, Tangen CM, et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation 2000 10; 102:1773-1779.
98. DeVane CL. Differential pharmacology of newer antidepressants. J Clin Psychiatry 1998; 59:(suppl 20):85-93.
99. Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety 1998; 7(suppl 1):24-32.
100. Fait ML, Wise MG, Jachna JS, et al. Psychopharmacology. In: Wise MG, Rundell JR, eds. The American Psychiatric Publishing Textbook of Consultation-Liaison Psychiatry. Psychiatry in the Medically ill. 2nd ed. Washington DC: American Psychiatric Publishing; 2002:939-988.
101. Nemeroff CB, DeVane LC, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153:311-320.
102. Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 2000; 12(suppl 1):30-44.
103. Michalets LE. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18:84-112.
104. Shader RI, von Moltke LL, Schmider J, Harmatz JS, Greenblatt DJ. The clinician and drug interactions - an update. J Clin Psychopharmacol 1996; 16:197-201.